Atrogi on its challenger to GLP-1: “Now we are stepping forward”
A new approach to treating type 2 diabetes and obesity is taking shape in a laboratory just a stone’s throw from the Karolinska Institute. At Atrogi, researchers are developing a potential challenger to today’s GLP-1.
It is a windy, rain-soaked December day at the Scheele Laboratory, just next to the Karolinska Institute. But five floors up in the red-brick building, the sense of engagement is unmistakable. This is home to biotech company Atrogi, with 14 employees and a newly appointed CEO at the helm.
“Perhaps I’m sitting here with a future Nobel laureate,” says Paul Little, nodding towards Professor Tore Bengtsson, the company’s founder.
News in English
BREAKING